Actively Recruiting
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Led by iCell Gene Therapeutics · Updated on 2025-09-16
12
Participants Needed
2
Research Sites
365 weeks
Total Duration
On this page
Sponsors
I
iCell Gene Therapeutics
Lead Sponsor
I
iCAR Bio Therapeutics Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
CONDITIONS
Official Title
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent; Patients volunteer to participate in the research
- Diagnosis is mainly based on the World Health Organization (WHO) 2008
- Patients have exhausted standard therapeutic options
- Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
- Female must be not pregnant during the study
You will not qualify if you...
- Patients declining to consent for treatment
- Prior solid organ transplantation
- Potentially curative therapy including chemotherapy or hematopoietic cell transplant
- Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Peking University Shenzhen Hospital, China
Shenzhen, Guangdong, China
Actively Recruiting
2
Chengdu Military General Hospital
Chengdu, Sichuan, China
Actively Recruiting
Research Team
K
Kevin Pinz, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here